Castle Creek Biosciences

Exton, PA · Founded 2015 · Privately Held (backing)

Developer of a fibroblast based therepy designed to treat rare and serious genetic diseases. Castle Creek Biosciences is based in Exton, PA and was founded in 2015. It has raised $419 million across 4 recorded rounds; the latest was a $75 million later-stage round in Feb 2025.

PMV mark · valuation
—
Oct 2026
Priced at
—
Total raised
$419.4M
Last round
Later Stage VC
Feb 2025
Valuation — not yet established

No valuation for Castle Creek Biosciences is on record yet — no priced round, mark, or trade has surfaced in our sources. Total raised ($419.4M) and the funding record below are the closest available signals.

Pro members can request priority coverage with a 48-hour turnaround.
Pro
The prices on Castle Creek Biosciences
  • ·57 fund marks: filer, period, implied $/share
Pro · $99 a month
List $299 · founding price, locked for as long as you stay

Membership and data by Private Market View

Castle Creek Biosciences funding history

4 rounds
DateRoundRaisedPost-money
Feb 2025Later Stage VC$75.0M▮
Apr 2022Later Stage VC$112.8M▮
Jan 2022Debt$11.8M▮
Jun 2021Debt$25.0M▮
Unlock post-money valuations

Membership and data by Private Market View

Recent activity

In the last 90 days, Castle Creek Biosciences's record added 7 institutional fund marks (latest period Jul 2026).

How much has Castle Creek Biosciences raised?

Castle Creek Biosciences has raised $419 million across 4 recorded rounds since 2021. The largest was a $75 million later-stage round in Feb 2025.

Castle Creek Biosciences has filed 4 Form Ds with the SEC since 2021, most recently in Feb 2025 ($75 million sold to 30 investors).

Institutional holders and vehicles

2 SEC-registered funds reported 57 fair-value marks on Castle Creek Biosciences between Apr 2025 and Jul 2026, in their N-PORT filings. Filer-level marks and implied per-share values are available to Pro members.

How Castle Creek Biosciences's valuation is determined

Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.

For Castle Creek Biosciences, the most current credible signal sets the number and the older ones confirm it: a live secondary-market price first, then three or more recent prints, then institutional fund marks, and otherwise the last priced round, which never decays. The valuation is the last round’s post-money moved by the price change since that round, so no share count is assumed. Today it is set by institutional fund marks. Question about this number? Full methodology →

Frequently asked about Castle Creek Biosciences

How much has Castle Creek Biosciences raised?
Castle Creek Biosciences has raised $419.4M in total funding across 4 recorded rounds.
When did Castle Creek Biosciences last raise?
Castle Creek Biosciences last raised in Feb 2025 (Later Stage VC), raising $75.0M.